Blue Horizon International Founder and Chief Medical Officer Shares the Importance of Stem Cell Therapy

Share Article

Stem Cell Therapy Support Advances in the Treatment of Musculoskeletal Conditions

Blue Horizon International, a healthcare organization that combines treatment, research, and philanthropic efforts to offer quality care and services for emerging markets across the globe, announced today that Chief Medical Officer, Brian Mehling, M.D., is available to discuss the importance of stem cell therapy in therapeutic advancements for the treatment of musculoskeletal conditions. Some of the most common diseases in this category include Osteoporosis, Sarcopenia, Arthritis, and Muscular Dystrophy.

Musculoskeletal conditions are the cause of severe long-term pain and physical disability, and affect millions of people around the world. Osteoarthritis is the most common form of arthritis and the leading cause of chronic disability. It is estimated that 630 million people are affected by this worldwide and the condition is characterized by degeneration of articular cartilage, limited intra-articular inflammation with synovitis, and changes in periarticular and subchondral bone.

With the discovery of new treatments and medical advances in research, patients affected by osteoarthritis pain and symptoms now have new hope. BHI Therapeutic Sciences, a division of Blue Horizon International, as a healthcare research and consulting company with the focus on high-quality advanced stem cell therapies for musculoskeletal conditions, shares that autologous adipose derived stem cell therapy has been proposed as a potential regenerative cell therapy source for patients suffering from this condition.

“At BHI Therapeutic Sciences, we offer a novel method of arthritis therapy using a patient’s own stromal vascular fraction cells including mesenchymal stem cells,” said Dr. Brian Mehling, Chief Medical Officer at Blue Horizon International. “The patients we have treated have seen a significant improvement and within one year; stem cell therapy has helped 60% of patients with knee osteoarthritis and 65% of patients suffering from coxarthrosis.”

BHI Therapeutic Sciences provides stem cell therapy in Slovakia through Malacky Hospital, one of the premiere and fully-licensed facilities to perform cord blood and adipose tissue-derived stem cell treatments.

To learn more, please visit: http://www.BHIsciences.com.

About Blue Horizon International
Blue Horizon International is a healthcare consulting company with a unique mission that combines treatment, research and philanthropic efforts. Across the globe quality care and services for medical treatments are provided along with resources needed to assist children and adults who are medically underserved. For more information please visit Blue Horizon International at http://www.BlueHorizonInternational.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rubenstein
Public Relations
+1 (212) 805-3057
Email >
Visit website